SCHEMBL16307315

SCHEMBL16307315

Cc1ccc(F)c2c1[C@@H](NS(N)(=O)=O)CC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 6/20 0.42
CA2 P00918 6/20 0.42
CYP1A2 P05177 1/20 0.32
HTR1A P08908 1/20 0.32
CYP2D6 P10635 1/20 0.32
DRD2 P14416 1/20 0.32
PKM P14618 1/20 0.32
ALOX15 P16050 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
CYP2C8 P10632 1/20 0.31
CYP2C9 P11712 1/20 0.31
FFAR1 O14842 1/20 0.31
CYP11B2 P19099 3/20 0.31
KMT2A Q03164 2/20 0.31
TDP1 Q9NUW8 1/20 0.31
CYP11B1 P15538 1/20 0.31
LMNA P02545 2/20 0.31
PMP22 Q01453 2/20 0.31
GLA P06280 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16307314 1.00 CA1 (0.42) CA1CA2CYP1A2HTR1ACYP2D6
SCHEMBL16290393 1.00 CA1 (0.42) CA1CA2CYP1A2HTR1ACYP2D6
SCHEMBL16290717 0.88 CA1 (0.46) CA1CA2CYP1A2HTR1ACYP2D6
SCHEMBL18710482 0.88 CA1 (0.46) CA1CA2CYP1A2HTR1ACYP2D6
SCHEMBL16290406 0.83 CA1 (0.42) CA1CA2CYP11B2KMT2ATDP1
SCHEMBL16307305 0.83 CA1 (0.42) CA1CA2CYP11B2KMT2ATDP1
SCHEMBL16307317 0.77 CA1 (0.42) CA1CA2CYP2C8CYP2C9FFAR1
SCHEMBL16290339 0.77 CA1 (0.42) CA1CA2CYP2C8CYP2C9FFAR1
SCHEMBL18710484 0.77 FFAR1 (0.32) DRD2CYP2C8CYP2C9FFAR1CYP11B2
SCHEMBL16290386 0.77 CA1 (0.44) CA1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2865663-B1 NOVEL INDANESULFAMIDE DERIVATIVE EISAI R&D MAN CO LTD (JP) 2017-04-05 EP disclosed
EP-2865663-A1 NOVEL INDANESULFAMIDE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2015-04-29 EP disclosed
US-9018260-B2 Indanesulfamide derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-28 US disclosed
US-9018260-B2 Indanesulfamide derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-28 US disclosed
US-20140371319-A1 NOVEL INDANESULFAMlDE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-12-18 US disclosed
US-20140371319-A1 NOVEL INDANESULFAMlDE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371319-A1 NOVEL INDANESULFAMlDE DERIVATIVES SCN1A, SCN7A, SCN2A CA1 219/4885CA2 315/4885CYP1A2 1489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.